Article | April 30, 2012
The Quest To Reinfuse Venture Capital Into Biotech Funding
Why Big Pharma needs to take a new approach to investing in early-stage biotech companies for the health of their pipelines, the industry, and ultimately, patients. By Sara Gambrill, contributing editor
